Xenova Group PLC -- Tariquidar Phase I Paediatric Study Data Presented at ASCO SLOUGH, U.K., June, 7 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that the Paediatric Oncology Branch of the National Cancer Institute (NCI) in Bethesda, U.S.,...

Xenova and FDA reach agreement on SPA Phase III trial programme for TransMID -- Enrollment to Begin Immediately SLOUGH, U.K. May 11, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that it has reached agreement with the US Food and Drug Administration (FDA) under the Special...

Xenova Group plc First Quarter Results, 2004 SLOUGH, U.K., May 6, 2004 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the quarter ended 31 March 2004. Year to Date Highlights * Revenue recognised for...

Xenova Signs Lease Agreement with Genzyme SLOUGH, U.K., April 7, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that it has signed a 10 year agreement with Genzyme Limited ("Genzyme") leasing to them the vacant...

Xenova Group plc -- Preliminary Results for the Year Ended 31 December 2003 SLOUGH, U.K., Feb. 24, 2004 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the year ended 31 December 2003. Highlights: -- Acquisition of KS Biomedix...